Subscribe to Newsletter

Trends & Forecasts

Business & Regulation Business Practice

The New Age of Global, Political, and Regulatory Challenges

| 7 min read

A report attempts to unravel the many challenges that face business leaders. We discuss those inherent in the pharmaceutical industry.

Business & Regulation Business Practice

What Trump’s Latest Moves Mean for the Industry

| 6 min read

Audrey Greenberg’s latest insight on US-based manufacturing, Trump’s “Administration for A Healthy America”

Discovery & Development Translational Science

Shifting to Animal-Free Drug Development

| Tomasz Kostrzewski | 5 min read

The FDA says it wants to phase out mandatory animal testing requirements for drug approval. What comes next?

Manufacture Marketing

Pharma Braces for Economic Downturn

| 4 min read

We ask an analyst how pharma companies can weather the volatile economic environment and the Trump administration’s tariffs.

Business & Regulation Standards & Regulation

The Trump Effect on Biopharma: FDA Disruption, Tariffs, and Funding Cuts

| 5 min read

Trump continues to send shockwaves through the industry. We look at FDA disruption, tariffs, funding volatility, and more.

Business & Regulation Profession

Denmark and Sweden Invite Misplaced US Scientists to the EU

| Rob Coker | 2 min read

Many US researchers are at odds with the imposition of Trump’s political agendas. EU member states are looking to take advantage.

Discovery & Development Clinical Trials

Making Clinical Trials Family Friendly

| Katherine Seay | 4 min read

Can making clinical trials more family friendly help increase the number of female participants?

Business & Regulation Business Practice

Breaking Down Brain Barriers

| Agnese Cattaneo | 3 min read

As mental health disorders escalate, pharmaceutical innovators can harness advanced tools to accelerate much-needed treatments.

Business & Regulation Trends & Forecasts

This Week’s Biopharma News: Roche’s $50 Billion Investment in the US and More

| 4 min read

Our latest news roundup reports on Roche’s US investment, a lawsuit against Vertex Pharmaceuticals, and more.

Business & Regulation Trends & Forecasts

Quality Over Quantity: EMA's New Approach to Biosimilars

| Rob Coker | 2 min read

EMA reflection paper considers elimination of routine comparative efficacy studies for biosimilars.


Latest White Papers

Early stage product development using laser diffraction analysis

| Contributed by Malvern Panalytical

All White Papers

Sister Publications

You might be interested in our Sister Publications:

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register

May Issue of The Medicine Maker